Search Results
483 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Appoints Robert Chisholm as CFO
His financial expertise is exactly what the company needs as we work to improve operational efficiency Chisholm served as CFO for PNI Digital Media (formerly PhotoChannel Networks Inc.) and subsequently joined Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Comments on President Obama's National Plan to Fight Alzheimer's Disease
About Alzheimer’s While Alzheimer’s is most common in people over the age of 65, it can strike adults Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Successfully Completes a Phase 1 Clinical Trial for ANAVEX 2-73
About Alzheimer’s Disease While Alzheimer’s Disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Dr. George Tidmarsh as Executive Director
Most recently, Dr. Tidmarsh’s background includes various positions at Coulter Pharmaceuticals, including Chief Medical Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Announces Director Resignation
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex to Present Data on ANAVEX 2-73, Lead Compound for Alzheimer's Disease
(“Anavex”) (OTCBB: AVXL) will present the most recent data showing the therapeutic potential of ANAVEX The most recent data suggested that ANAVEX 2-73 could alleviate the generation of newly formed amyloid-beta About Alzheimer’s Disease While Alzheimer’s disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Presents Data on Neuroprotective Evidence for ANAVEX 2-73, Lead Compound for AD
these compounds could be compared to donepezil, which is the market leader in Alzheimer’s disease (AD) medication The posters are available on the Anavex web site: https://anavex.com//files/AAIC_Poster_Tangui_July_2011 .pdf and https://anavex.com//files/AAIC_Poster_Tangui_tau_July_2011.pdf. About Alzheimer’s Disease While Alzheimer’s disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Presents Data on Potential Dual Utility of ANAVEX 2-73 in Both Amyloid and Tau Pathology
The poster is available on the Anavex web site: https://anavex.com//files/AAIC_Poster_Tangui_tau_July Breaking studies captured global media attention as the world’s leading experts explored innovative ways About Alzheimer’s Disease While Alzheimer’s disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Raises $1.575 million
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Rapidly Advances ANAVEX 2-73 for Alzheimer’s Disease, Phase I Clinical Trial Progressing Well
Specifically, there is evidence of ‘neuroprotection’ — in other words certain brain cells that are ordinarily lost About Alzheimer’s Disease While Alzheimer’s disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Advances Second Lead Compound; Initiates Scale-Up Manufacturing of ANAVEX 1-41
Angelos Stergiou, VP of Clinical Development and Medical Affairs for Anavex. Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- ANAVEX 2-73 Advances Phase I Clinical Trial for Alzheimer’s Disease
Angelos Stergiou, Vice President of Clinical Development and Medical Affairs for Anavex. Clinical Pharmacologist and Principal Investigator for the ANAVEX 2-73 Phase I clinical trial at the Medical About Alzheimer’s Disease While Alzheimer’s disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
